Clinical Trial Update: BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BAY81-8781, an intravenous aspirin formulation, for acute coronary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• BAY81-8781 (acetylsalicylic acid, intravenous formulation)

Snippet

Sponsor: Bayer | Conditions: Acute Coronary Syndrome | Phase 3 | Status: COMPLETED